NCT00980460 2026-03-18
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01687673 2020-12-07
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT01335074 2016-11-15
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Philipps University Marburg
Phase 1/2 Withdrawn
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01079767 2014-03-04
Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT01281943 2013-07-04
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Washington University School of Medicine
Phase 2 Withdrawn
NCT00087074 2013-06-04
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Phase 2 Completed
NCT01567930 2012-12-17
Temsirolimus as Second-line Therapy in HCC
University of Tennessee Cancer Institute
Phase 2 Unknown
NCT00593008 2011-12-02
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated